ÈËÉú¾ÍÊDz©

EN
ÈËÉú¾ÍÊDz©_Ê×Ò³Èë¿Ú ÈËÉú¾ÍÊDz©_Ê×Ò³Èë¿Ú
ÐÂÎÅÖÐÐÄ
2024-05-20
¿ÆÑ§¼Ò·¢Ã÷ÔöÇ¿¹¤³Ì»¯Tϸ°ûÃâÒßÖÎÁƵÄÐÂÐÍÔª¼þ
¿ËÈÕ£¬ £¬£¬ÄÏ·½Ò½¿Æ´óѧÄÏ·½Ò½Ôº·¢Ã÷ÔöÇ¿Tϸ°ûÊÜÌ幤³Ì»¯Tϸ°û£¨TCR-T£©ÃâÒßÖÎÁƵÄÐÂÐÍÔª¼þ¡£¡£¡£Ïà¹ØÐ§¹ûÔÚÏß½ÒÏþÓÚ¡¶ÐźÅתµ¼Óë°ÐÏòÖÎÁÆ¡·£¨Signal Transduction and Targeted Therapy£©¡£¡£¡£
ÔĶÁ¸ü¶à
2024-05-18
ÐÂÒ»´ú»ùÒòÖÎÁÆÎªÕâÖֻư߱äÐÔ»¼Õß´øÀ´¸ü¶àÒæ´¦
¿ËÈÕ£¬ £¬£¬¡¶×ÔÈ»-ͨѶ¡·¿¯·¢ÁËÒ»ÏîËÄ´¨´óѧ»ªÎ÷ҩѧԺËïÑ·½ÌÊÚµÈÍŶӹØÓÚÐÂÉúѪ¹ÜÐÔ£¨ÊªÐÔ£©ÄêËêÏà¹ØÐԻư߱äÐÔ£¨nAMD£©»ùÒòÖÎÁÆÒ©ÎïµÄÁÙ´²Ç°Ñо¿Êý¾Ý¡£¡£¡£Ñо¿ÏÔʾ£¬ £¬£¬ÔÚÈËÊÓÍøÄ¤É«ËØÉÏÆ¤Ï¸°û19£¨ARPE19£©ÉÏ£¬ £¬£¬Ó¦Óúë»ùÉúÎïAAVÒ¿Çɸѡƽ̨´òÔìµÄÈ«ÐÂÑÛ¿ÆAAVÒ¿DZäÌ塪¡ªAAVv128±ÈAAV8£¬ £¬£¬ÔÚϸ°ûÁ¬Ïµ·½ÃæÌá¸ßÁË30.8±¶£¬ £¬£¬ÔÚϸ°ûÉãÈ¡·½ÃæÌá¸ßÁË24.7±¶¡£¡£¡£
ÔĶÁ¸ü¶à
2024-05-16
×îÐÂÑо¿Õ¹ÏÖCAR-TµÄÖÐÊàÉñ¾­ÃâÒßÖØËÜ»úÖÆ
¼ÇÕß´Ó»ªÖпƼ¼´óѧͬ¼ÃҽѧԺÁ¥Êôͬ¼ÃÒ½Ôº»ñϤ£¬ £¬£¬¸ÃÔºÉñ¾­ÄÚ¿ÆÍõΰ½ÌÊÚ¡¢Ìï´úʵ½ÌÊÚÍŶÓÈÕǰÔÚ¹ú¼ÊȨÍþѧÊõÆÚ¿¯¡¶¿ÆÑ§¡·×Ó¿¯¡¶¿ÆÑ§ÃâÒßѧ¡·ÉϽÒÏþÁ˹ØÓÚCAR-Tϸ°ûÖÎÁÆÊÓÉñ¾­¼¹ËèÑׯ×ϵ¼²²¡»¼Õߵĵ¥Ï¸°û¶à×éѧÆÊÎöµÄÑо¿ÂÛÎÄ£¬ £¬£¬ÔÚµ¥Ï¸°ûˮƽϵͳÃè»æ³öCAR-Tϸ°ûÔÚ×ÔÉíÃâÒß¼²²¡»¼ÕßÌåÄڵĶ¯Ì¬×ª±ä¹ì¼£¡£¡£¡£Ïà¹ØÑо¿Õ¹ÏÖÁËCAR-Tϸ°ûÖÎÁÆÖÐÊàÉñ¾­ÏµÍ³ÃâÒßÐÔ¼²²¡µÄÖÐÊàÉñ¾­ÃâÒßÖØËÜ»úÖÆ¡£¡£¡£
ÔĶÁ¸ü¶à
2024-05-15
ÎÒ¹úÑо¿ÍŶӷ¢Ã÷µ÷¿ØTϸ°ûÖ×ÁöÃâÒß¹¦Ð§µÄÉúÎïÁ¦Ñ§¼ì²éµã
5ÔÂ13ÈÕ£¬ £¬£¬ÏÃÃÅ´óѧÉúÃü¿ÆÑ§Ñ§Ôº/Ïè°²Ò½ÔºÖÜ´óÍú½ÌÊÚ¡¢³ÂÀ¼·Ò½ÌÊÚ¼°Â½¾ü¾üÒ½´óѧÃâÒßѧÑо¿ËùÒ¶ÀöÁÖ½ÌÊÚµÈÔÚ¹ú¼Ê¶¥¼âѧÊõÆÚ¿¯CellÉϽÒÏþÁËÌâΪ¡°Osr2 functions as a biomechanical checkpoint to aggravate CD8+ T cell exhaustion in tumor ¡±µÄÑо¿ÂÛÎÄ¡£¡£¡£
ÔĶÁ¸ü¶à
2024-05-14
×ÔÉíÃâÒßÐÔ¼²²¡ÓëXȾɫÌå»ùÒòÖØÐ¼¤»îÓйØ
Ò»ÏîÕë¶ÔСÊóµÄÑо¿Åú×¢£¬ £¬£¬´ÆÐÔ²¸È鶯ÎﻼÀÇ´¯µÈ×ÔÉíÃâÒßÐÔ¼²²¡µÄΣº¦¸ü¸ß£¬ £¬£¬ÓÉÓÚËæ×ÅÄêËêµÄÔöÌí£¬ £¬£¬XȾɫÌåʧ»îµÄ»ùÒòÓÖ»á±»ÖØÐ¼¤»î¡£¡£¡£Ïà¹ØÂÛÎÄ¿ËÈÕ½ÒÏþÓÚ¡¶¿ÆÑ§Ï£Íû¡·¡£¡£¡£
ÔĶÁ¸ü¶à
2024-05-14
ÐÞ¸´ÊÜËð¸ÎÔàµÄÐÂÐÍϸ°û·¢Ã÷
Ó¢¹ú¿ÆÑ§¼ÒÔÚ¸ÎÔàÄÚ·¢Ã÷ÁËÒ»ÖÖ±»³ÆÎª¡°Ïòµ¼Ï¸°û¡±µÄÐÂÐÍϸ°û¡£¡£¡£ËüÃÇÔÚ¸ÎÔàÊÜËðºó¾ÙÐÐ×ÔÎÒÐÞ¸´·½ÃæÊ©Õ¹ÁËÖ÷Òª×÷Óᣡ£¡£Ñо¿Ö°Ô±ÌåÏÖ£¬ £¬£¬ÕâÒ»·¢Ã÷ÓÐÍû´ßÉúеĸβ¡ÁÆ·¨¡£¡£¡£Ïà¹ØÂÛÎĽÒÏþÓÚÐÂÒ»ÆÚ¡¶×ÔÈ»¡·ÔÓÖ¾¡£¡£¡£
ÔĶÁ¸ü¶à
2024-05-13
Ñо¿·¢Ã÷CAR-M¸ßЧÔÙÍâÐÐÒÕ¿ÉÓÃÓÚÖ×ÁöÖÎÁÆ
¿ËÈÕ£¬ £¬£¬Öйúҽѧ¿ÆÑ§ÔºÑªÒº²¡Ò½Ôº£¨Öйúҽѧ¿ÆÑ§ÔºÑªÒºÑ§Ñо¿Ëù£©½ÌÊÚ³ÌÌΡ¢Éò¿¡¡¢Íõ½¨ÏéÍŶӼ°ÖÐɽ´óѧҽѧԺ½ÌÊÚÀîê¿ÍŶÓÏàÖúÎ§ÈÆ¡°Ð§ÂÊ¡±ºÍ¡°Ò©Ð§¡±£¬ £¬£¬¿ª·¢ÁËÈ˶àÐÑĿϸ°û£¨hPSC£©¶¨ÏòǶºÏ¿¹Ô­ÊÜÌå¾ÞÊÉϸ°û£¨CAR-M£©¸ßЧÓÕµ¼·Ö½âϵͳ£¬ £¬£¬²¢Í¨¹ýÁªºÏ¼¤»î¹ÌÓÐ-˳ӦÐÔÃâÒßʵÏÖÁËhPSC-CAR-MµÄÌåÄÚÇ¿¾¢¿¹Ö×ÁöЧӦ¡£¡£¡£Ïà¹ØÑо¿½ÒÏþÓÚ¡¶Ï¸°û¡¤¸Éϸ°û¡·¡£¡£¡£
ÔĶÁ¸ü¶à
2024-05-12
ÎÒ¹ú¿ÆÑ§¼ÒÕ¹ÏÖÖ×Áö½þÈóBϸ°ûµÄÁ½ÖÖÓ¦´ðģʽ
ÔÚÒ»ÏîеÄÑо¿ÖУ¬ £¬£¬À´×ÔÖйú¿ÆÑ§ÔºÉϺ£ÃâÒßÓëѬȾÑо¿Ëù¡¢¸´µ©´óѧºÍÕã½­´óѧµÄÑо¿Ö°Ô±Õ¹ÏÖÁËÖ×Áö½þÈóBϸ°ûµÄÁ½ÖÖÓ¦´ðģʽ£¬ £¬£¬¾ßÓÐÖÎÁÆÒâÒå¡£¡£¡£Ïà¹ØÑо¿Ð§¹û¿ËÈÕÔÚScienceÆÚ¿¯ÉϽÒÏþ£¬ £¬£¬ÂÛÎÄÎÊÌâΪ¡°A blueprint for tumor-infiltrating B cells across human cancers¡±¡£¡£¡£
ÔĶÁ¸ü¶à
¡¾ÍøÕ¾µØÍ¼¡¿